<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">58376</article-id><article-id pub-id-type="doi">10.7554/eLife.58376</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Lymphangiogenic therapy prevents cardiac dysfunction by ameliorating inflammation and hypertension</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-186323"><name><surname>Song</surname><given-names>LouJin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-186325"><name><surname>Chen</surname><given-names>Xian</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-186324"><name><surname>Swanson</surname><given-names>Terri A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-186339"><name><surname>LaViolette</surname><given-names>Brianna</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-186340"><name><surname>Pang</surname><given-names>Jincheng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-211985"><name><surname>Cunio</surname><given-names>Teresa</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-211986"><name><surname>Nagle</surname><given-names>Michael W</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" id="author-186342"><name><surname>Asano</surname><given-names>Shoh</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf9"/></contrib><contrib contrib-type="author" id="author-186343"><name><surname>Hales</surname><given-names>Katherine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf10"/></contrib><contrib contrib-type="author" id="author-186344"><name><surname>Shipstone</surname><given-names>Arun</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf11"/></contrib><contrib contrib-type="author" id="author-186345"><name><surname>Sobon</surname><given-names>Hanna</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf12"/></contrib><contrib contrib-type="author" id="author-211987"><name><surname>Al-Harthy</surname><given-names>Sabra D</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf13"/></contrib><contrib contrib-type="author" id="author-186346"><name><surname>Ahn</surname><given-names>Youngwook</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf14"/></contrib><contrib contrib-type="author" id="author-186347"><name><surname>Kreuser</surname><given-names>Steven</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf15"/></contrib><contrib contrib-type="author" id="author-186348"><name><surname>Robertson</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf16"/></contrib><contrib contrib-type="author" id="author-186349"><name><surname>Ritenour</surname><given-names>Casey</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf17"/></contrib><contrib contrib-type="author" id="author-186350"><name><surname>Voigt</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf18"/></contrib><contrib contrib-type="author" id="author-186351"><name><surname>Boucher</surname><given-names>Magalie</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf19"/></contrib><contrib contrib-type="author" id="author-186352"><name><surname>Sun</surname><given-names>Furong</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf20"/></contrib><contrib contrib-type="author" id="author-22561"><name><surname>Sessa</surname><given-names>William C</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5759-1938</contrib-id><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-185532"><name><surname>Roth Flach</surname><given-names>Rachel J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2754-828X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf21"/></contrib><aff id="aff1"><institution content-type="dept">Internal Medicine Research Unit</institution>, <institution>Pfizer Inc</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Comparative Medicine</institution>, <institution>Pfizer Inc</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Early Clinical Development</institution>, <institution>Pfizer Inc</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution>Acceleron Pharma</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution>Eisai Inc</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">Inflammation and Immunology</institution>, <institution>Pfizer Inc</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff7"><institution content-type="dept">Emerging Science and Innovation</institution>, <institution>Pfizer Inc</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff8"><institution content-type="dept">Drug Safety Research &amp; Development</institution>, <institution>Pfizer Inc</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff9"><institution content-type="dept">Pharmacology</institution>, <institution>Yale School of Medicine</institution>, <addr-line><named-content content-type="city">New Haven</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-57759"><name><surname>Koh</surname><given-names>Gou Young</given-names></name><role>Reviewing editor</role><aff><institution>Institute of Basic Science and Korea Advanced Institute of Science and Technology (KAIST)</institution>, <country>Korea (South), Republic of</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>Rachel.RothFlach@pfizer.com</email> (RR);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>17</day><month>11</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e58376</elocation-id><history><date date-type="received"><day>29</day><month>04</month><year>2020</year></date><date date-type="accepted"><day>16</day><month>11</month><year>2020</year></date></history><permissions><copyright-statement>Â© 2020, Song et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Song et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-58376-v1.pdf"/><abstract><p>The lymphatic vasculature is involved in the pathogenesis of acute cardiac injuries, but little is known about its role in chronic cardiac dysfunction. Here, we demonstrate that angiotensin II infusion induced cardiac inflammation and fibrosis at 1 week and caused cardiac dysfunction and impaired lymphatic transport at 6 weeks in mice, while co-administration of VEGFCc156s improved these parameters. To identify novel mechanisms underlying this protection, RNA sequencing analysis in distinct cell populations revealed that VEGFCc156s specifically modulated angiotensin II-induced inflammatory responses in cardiac and peripheral lymphatic endothelial cells. Furthermore, telemetry studies showed that while angiotensin II increased blood pressure acutely in all animals, VEGFCc156s-treated animals displayed a delayed systemic reduction in blood pressure independent of alterations in angiotensin II-mediated aortic stiffness. Overall, these results demonstrate that VEGFCc156s had a multifaceted therapeutic effect to prevent angiotensin II-induced cardiac dysfunction by improving cardiac lymphatic function, alleviating fibrosis and inflammation, and ameliorating hypertension.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004319</institution-id><institution>Pfizer</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Roth Flach</surname><given-names>Rachel J</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>LouJin Song, is an employee at Pfizer inc.</p></fn><fn fn-type="conflict" id="conf3"><p>Xian Chen, is an employee at Pfizer inc.</p></fn><fn fn-type="conflict" id="conf4"><p>Terri A Swanson, is an employee at Pfizer inc.</p></fn><fn fn-type="conflict" id="conf5"><p>Brianna LaViolette, is an employee at Pfizer inc.</p></fn><fn fn-type="conflict" id="conf6"><p>Jincheng Pang, is an employee at Pfizer inc.</p></fn><fn fn-type="conflict" id="conf7"><p>Teresa Cunio, was an employee at Pfizer inc and is currently an employee at Acceleron Pharma.</p></fn><fn fn-type="conflict" id="conf8"><p>Michael W Nagle, was an employee at Pfizer Inc. and is currently an employee at Eisai Inc.</p></fn><fn fn-type="conflict" id="conf9"><p>Shoh Asano, is an employee at Pfizer Inc.</p></fn><fn fn-type="conflict" id="conf10"><p>Katherine Hales, is an employee at Pfizer Inc.</p></fn><fn fn-type="conflict" id="conf11"><p>Arun Shipstone, is an employee at Pfizer Inc.</p></fn><fn fn-type="conflict" id="conf12"><p>Hanna Sobon, is an employee at Pfizer Inc.</p></fn><fn fn-type="conflict" id="conf13"><p>Sabra D Al-Harthy, is an employee at Pfizer Inc.</p></fn><fn fn-type="conflict" id="conf14"><p>Youngwook Ahn, is an employee at Pfizer Inc.</p></fn><fn fn-type="conflict" id="conf15"><p>Steven Kreuser, is an employee at Pfizer Inc.</p></fn><fn fn-type="conflict" id="conf16"><p>Andrew Robertson, is an employee at Pfizer Inc.</p></fn><fn fn-type="conflict" id="conf17"><p>Casey Ritenour, is an employee at Pfizer Inc.</p></fn><fn fn-type="conflict" id="conf18"><p>Frank Voigt, is an employee at Pfizer Inc.</p></fn><fn fn-type="conflict" id="conf19"><p>Magalie Boucher, is an employee at Pfizer Inc.</p></fn><fn fn-type="conflict" id="conf20"><p>Furong Sun, is an employee at Pfizer Inc.</p></fn><fn fn-type="conflict" id="conf21"><p>Rachel J Roth Flach, is an employee at Pfizer Inc.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: The ethics statement has been included in the method section of the manuscript as the following:&quot;All animal experimental procedures were carried out in accordance with regulations and established guidelines and were reviewed and approved by the Pfizer Institutional Animal Care and Use Committee(AUP # KSQ-2013-00895).&quot;</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>RNA-Seq data has been deposited in GEO under accession code GSE150041. All other data generated during the study are included in the manuscript and supporting files. Source data has been provided for Figure 1-7.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Song L</collab><collab>Shipstone A</collab><collab>Nagle MW</collab></person-group><year iso-8601-date="2020">2020</year><source>RNA sequencing study using Prox1-eGFP mice to investigate the role of lymphatic vasculature in chronic cardiac dysfunction</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE150041">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE150041</ext-link><comment>NCBI Gene Expression Omnibus, GSE150041</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-58376-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>